Merkzettel Warenkorb

Gutscheinbedingungen

**Gültig vom 20.07.2026 bis 22.07.2026 | Gültig für nicht preisgebundene fremdsprachige Bücher | Einzelne Artikel können ausgeschlossen sein | Nicht kombinierbar mit anderen Gutscheinen oder Preisaktionen | Nur einmal pro Einkauf einlösbar | Gutschein wird auf max. 500€ Bestellwert angerechnet | Keine Barauszahlung | Nicht gültig für Versandkosten und Services
  • Produktbild: Adjuvant Therapy of Primary Breast Cancer VI
  • Produktbild: Adjuvant Therapy of Primary Breast Cancer VI
Band 152

Adjuvant Therapy of Primary Breast Cancer VI

Aus der Reihe Recent Results in Cancer Research

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Lieferung nach Hause

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.03.2012

Herausgeber

Hans-Jörg Senn + weitere

Verlag

Springer Berlin

Seitenzahl

506

Maße (L/B/H)

23,5/15,5/2,9 cm

Gewicht

791 g

Auflage

Softcover reprint of the original 1st ed. 1998

Sprache

Englisch

ISBN

978-3-642-45771-5

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.03.2012

Herausgeber

Verlag

Springer Berlin

Seitenzahl

506

Maße (L/B/H)

23,5/15,5/2,9 cm

Gewicht

791 g

Auflage

Softcover reprint of the original 1st ed. 1998

Sprache

Englisch

ISBN

978-3-642-45771-5

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Adjuvant Therapy of Primary Breast Cancer VI
  • Produktbild: Adjuvant Therapy of Primary Breast Cancer VI
  • I. Epidemiology and Its Lessons.- Diet and Mammary Gland Carcinogenesis.- Prevention of Breast Cancer: Focus on Chemoprevention.- Estrogen/Hormone Replacement Therapy and the Etiology of Breast Cancer.- II. Genetics of Breast Cancer.- Experimental Pathology and Breast Cancer Genetics: New Technologies.- Update on Breast Cancer Susceptibility Genes.- III. Biology of Breast Cancer: Diagnostic and Prognostic Implications.- IGF-I Physiology and Breast Cancer.- Determination of Clinical Utility of Tumor Markers: A Tumor Marker Utility Grading System.- How Can Prognostic and Predictive Factors in Breast Cancer Be Used in a Practical Way Today?.- Strategies for the Development of Vaccines to Treat Breast Cancer.- IV. In Situ Breast Cancer.- Hypothesis and Practice: Are There Several Types of Treatment for Ductal Carcinoma In Situ of the Breast?.- Ductal Carcinoma In Situ of the Breast: Histological Classification and Genetic Alterations.- Trials of Treatment for Non-invasive Breast Cancer.- Summary.- V. Controversies About the Axilla.- The Axilla: To Clear or Not to Clear? That Is the Question!.- Axillary Clearance in Operable Breast Cancer: Still a Necessity?.- Sentinel Lymphadenectomy: A Safe Answer to Less Axillary Surgery?.- Endoscopic Surgery to the Axilla: A Substitute for Conventional Axillary Clearance?.- VI. Integrated Therapy: Changing Surgical Procedures for Breast Cancer.- Surgical Considerations in Preoperative Chemotherapy of Breast Cancer.- Integration of Plastic Surgery in the Course of Breast-Conserving Surgery for Cancer to Improve Cosmetic Result and Radicality of Tumor Excision.- Summary.- VII. Integrated Therapy: Primary Adjuvant Systemic Therapy.- Is Primary Chemotherapy Useful for All Patients with Primary Invasive Breast Cancer?.- The Primary Use of Endocrine Therapies.- VIII. Integrated Therapy: Radiation Therapy/Endocrine Treatment.- Why and How to Combine Chemotherapy and Radiation Therapy in Breast Cancer Patients.- Novel Approaches Using Radiation Therapies.- Molecular Biology of the Estrogen Receptor Aids in the Understanding of Tamoxifen Resistance and Breast Cancer Prevention with Raloxifene.- Aromatase Inhibitors and Their Use in the Adjuvant Setting.- GnRH Analogues and Ovarian Ablation: Their Integration in the Adjuvant Strategy.- Summary.- IX. Adjuvant Systemic Treatments: Cytotoxic Strategies.- Putting the Taxanes to Work: Unanswered Questions.- Putting Taxanes to Work in Operable Breast Cancer: A Search for Selective Indications from Empirical Studies.- Continuous Infusional Chemotherapy for Early Breast Cancer: The Royal Marsden Hospital Experience.- Tailored Chemotherapy to Equal Toxicity: Is It Possible?.- Anti-angiogenesis Therapy and Strategies for Integrating It with Adjuvant Therapy.- X. Adjuvant Systemic Treatments: Cytotoxics and Their Dosage.- New Developments in High-Dose Chemotherapy for Breast Cancer.- Summary.- XI. Integrated Treatments: Quality of Life.- Quality of Life Assessment in the Adjuvant Setting: Is It Relevant?.- Quality of Life Assessment in the International Breast Cancer Study Group: Past, Present, and Future.- Impact of Different Adjuvant Therapy Strategies on Quality of Life in Breast Cancer Survivors.- Summary.- XII. Clinical Research Around the World: Review of Cooperative Group Trials.- North American Adjuvant Breast Cancer Trials.- International Breast Cancer Study Group Trials.- Nordic Trials of Adjuvant Therapy in Primary Breast Cancer.- The EORTC-Breast Cancer Cooperative Group Clinical Research Programme in Early Breast Cancer.- Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials.- Current Trials of the German Adjuvant Breast Cancer Group (GABG).- XIII. International Consensus Conference on Primary Treatment of the Breast: Update 1998.- International Consensus Panel on the Treatment of Primary Breast Cancer V: Update 1998.